NCT01936974

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Western Regional Medical Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma

Detailed description

This study will evaluate progression-free survival (PFS)for the regimen of gemcitabine and bevacizumab with or without a platinum agent on platinum-resistant/refractory ovarian and peritoneal carcinoma

Conditions

• Ovarian Carcinoma
• Fallopian Tube Carcinoma
• Peritoneal Carcinoma

Interventions

Type	Name	Description
DRUG	Gemcitabine	Patient to receive gemzar
DRUG	Bevacizumab	Patient to receive avastin
DRUG	Carboplatin	Patient to receive carboplatin
DRUG	Cisplatin	Patient to receive cisplatin
DRUG	Oxaliplatin	Patient to receive Oxaliplatin

Timeline

• Start date: 2013-09-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2013-09-06
• Last updated: 2018-02-20
• Results posted: 2017-10-25

Locations

1 site across 1 country: United States